1 IMPACT: the International Medical Products Anti-Counterfeiting Taskforce Peter Munyi LLM Christa Cepuch BSc Phm UNSR EAC Consultation, Nairobi 10 – 12.

Slides:



Advertisements
Similar presentations
4 th Global Congress Combating Counterfeiting & Piracy Dubai, February 3-8, 2008 Challenge 7 : Strengthening Cooperation and Collaboration at the Global.
Advertisements

الرابطة الدولية لمكافحة المواد الطبيّة المزورة a WHO initiative to combat counterfeit medical products Dr V. Reggi - World Health Organization.
Armand Racine Consultant Chemicals Branch
Trade and Health National Assessment The World Health Organisations Diagnostic Tool on Trade and Health Presented by: Corinna Hawkes, Consultant
IMPACT Principles and Elements for National Legislation Presented by: Chair, Working Group on Regulatory Implementation, on behalf of Chair, Working Group.
First ASEAN-China Conference on Combating Counterfeit Medical Products Jakarta November 2007 CHOO CHEOK HANG DEPARTMENT OF PHARMACEUTICAL SERVICES.
Technical cooperation with countries Technical Cooperation for essential drugs and traditional medicines September 2005.
2 nd WIPO Inter-Regional Meeting on South- South Cooperation on Patents, Trademarks, Geographical Indications, Industrial Designs and Enforcement Cairo.
Harnessing the power of the sun: SHAMCI (Solar Heating Arab Mark and Certification Initiative) Presentation by: Rim Boukhchina Technical expert - RCREEE.
1 Coordinating and Financing R&D in Developing Countries-moving beyond PDP's The ANDI Experience Solomon Nwaka CEWG on R&D Financing & Coordination, April.
Panel themes of the International Conference “Europe against Counterfeit Medicines” G.N. Gildeeva, Deputy head of the Department of Registration of Medicines.
1 |1 | Counterfeit Medical Products: Anti-Counterfeit Medicines programme update Dr Lembit Rägo Coordinator Quality Assurance and Safety: Medicines Essential.
The Emergence of Anti-Counterfeiting Legislation in East Africa: Implications for Generic Supply and Treatment Access Mandeep Dhaliwal Tenu Avafia With.
Strengthening the Protection of Intellectual and Industrial Property Rights Deputy Manager Jan Hylleberg The Danish Association of the Pharmaceutical Industry.
Asia-Pacific Finance and Development Centre 2006 Biennial Forum Shanghai, September 2006 Session V: Regional Cooperation and Innovation Development Presented.
World Health Organization
Public health, innovation and intellectual property 1 |1 | WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies Global Strategy and Plan.
Intellectual Property and Access to Affordable Medicines: TRIPS Plus
Regulations Relating to Foodstuffs for Infants and Young Children (Foodstuffs, Cosmetics and Disinfectants Act, 1972) Briefing to the Portfolio Committee.
Building Capacities for Management of IPRs in Countries in Transition. WIPO Tools. Tbilisi, November 12, 2012 Mr. Michal Svantner, Director, Division for.
The WIPO Development Agenda: An Overview Geneva May, 2009 Esteban Burrone World Intellectual Property Organization.
The emergence of an Enforcement Agenda Intellectual Property Rights and Access to Essential Medicines: Challenges and Opportunities in Free Trade Agreement.
Working with UICC’s 800+ member organisations in 155 countries, the McCabe Centre aims to build legal capacity globally. Based at CCV in Melbourne, Australia.
10. Workshop ERFP Uppsala, June 4, 2005 Proposals for an ERFP contribution to FAO Regional consultation on SoW- AnGR Hermann Schulte-Coerne.
CI Consumer Justice and Protection programme Indrani Thuraisingham CI Office for Asia-Pacific and the Middle East.
CEBS in Brief. The Lamfalussy approach The Lamfalussy approach was first implemented in the securities field following the recommendations of the Committee.
1 Examples of subregional collaboration: the experience of Operation Mamba I & II in East African Community (EAC) The case of TANZANIA IMPACT.
Strategic Plan Kidsafe NSW Inc.. ‘A Safer World for Kids’ Kidsafe NSW Inc.
“Commercialization and enforcement of intellectual property rights” - Skopje, April 2009 UNECE ‘Recommendation M’ on the Use of Market Surveillance.
A project implemented by the HTSPE consortium This project is funded by the European Union SECURITY AND CITIZENS SECURITY AND CITIZENSHIP CONSUMER
Regulatory requirements in the current programming period Funchal, 18 November 2010.
Making South Africa a Global Leader in Harnessing ICTs for Socio-economic Development SECRET 1 PRESENTATION TO THE PORTFOLIO COMMITTEE ON COMMUNICATIONS:
ICPHSO - Seoul 2011 “There’s a new kid in town”. ICPHSO - Seoul 2011 America’s Consumer Safety and Health Network – CSHN
Intellectual Property Rights and Pharmaceuticals (Following Up the ‘Novartis case’ ) Background note prepared for PHM Vic Internet Workshop.
The Role of Peer Review in a Multilateral Framework on Competition Policy Andrea Bruce Investment Trade Policy UNCTAD Regional Seminar for Latin America.
International cooperation in combating IP crimes: Criminal IP enforcement in the international policy debate Heike Wollgast World Intellectual Property.
Eurostat/UNSD Conference on International Outreach and Coordination in National Accounts for Sustainable Development and Growth 6-8 May, Luxembourg These.
IP Offices and the Implementation of the WIPO Development Agenda: Challenges and Opportunities September 18, 2009 Geneva Irfan Baloch World Intellectual.
Promoting Decent Work for All 1 Strategic Partnerships for Realizing Decent Work in Asia: ILO-ASEAN Cooperation August 23, 2007 Kee Beom Kim ILO Jakarta.
Alexandra Heumber Médecins Sans Frontières Access to Essential Medicines Campaign DEBRIEFING WHA May 2006.
Private Sector Consultative Group Report to the Policy Commission 9 June 2015 WCO Private Sector Consultative Group.
Preliminary classification of proposals by the CEWG Proposals for innovative financing: Discussing the work to-date of WHO’S Consultative Expert Working.
1 Competition policy in WTO sectoral agreements Dr. Pierre Arhel Counsellor (competition policy) Intellectual Property Division Sao Paulo, April.
IPRTA FORUM Mexico 08 Panel 1: Emerging challenges, opportunities and recent developments for IPRTA to developing countries Valentín Mir Director International.
Building Strong Library Associations | Sustaining Your Library Association BSLA Stakeholders Workshop Yaounde, Cameroon, April 2012 Managing Relationships.
TPO Services An institutional perspective By: Miguel CAMACHO & Ann PENISTAN, TS/DBIS Date: 31 March 2011.
Polish National Rural Network Bureau of Technical Assistance Responsible for: -Technical Assistance in Programs of Rural Development for period.
Developing an Operational Plan for PBOs Kevin Page Jean-Luc Pépin Chair in Canadian Government June 12, 2014 Global Network of PBOs Community Meeting.
Public health, innovation and intellectual property 1 |1 | The Global Strategy on Public Health, Innovation and Intellectual Property Technical Briefing.
WHO Regional Workshop on Good Manufacturing Practices for Blood Establishments Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines.
Group A: Angola – Mozambique – RdC –Mauritius - Kenya G roup B: Namibia – Seychelles - South Africa - Uganda Group C: Botswana - Lesotho – Swaziland -Tanzania.
-0- June 2006 Roles & Responsibilities vs. STAP Implementation.
“DEVELOPMENT OF A NATIONAL ICT POLICY ICT Policy in the ECTEL Member States Mr. Donnie Defreitas MSc, (Hav.), ECTEL Caribbean Internet Forum Bay Gardens.
IMPACT - Regional Meeting on Combating Counterfeit Medical Products 9-10 November 2009, Kempton Park South Africa WHO Survey on situation of counterfeit.
Overview of Good Regulatory Practice Kent Shigetomi Office of the U.S. Trade Representative.
Role of WHO as Technical Advisor to Ministry of Health West Bank and Gaza.
Implementation of PANDRH Guidelines NAFTA Region VI PANDRH Conference Brasilia, July 2-8, 2011 Justina Molzon -- US Food and Drug Administration Mike Ward.
Date: in 12 pts MARKET SURVEILLANCE IN THE EU ROLE IN THE NLF - EU ACTIONS and DEVELOPMENTS Rita L'Abbate European Commission DG ENTERPRISE AND INDUSTRY.
ITC-ILO/ACTRAV Course A Trade Union Training on Occupational Safety, Health & HIV/AIDS (26/11 – 07/12/2012, Turin) Introduction to National Occupational.
Josephine Muwonge Ass. Commissioner, HR Ministry of Trade, Industry and Cooperatives.
ACCESS TO QUALITY MEDICINES IN THE REGION-COUNTERFEITING PROBLEMS
EU Reference Centres for Animal Welfare
Ildiko Pataki – NATIONAL CENTRE FOR tvet DEVELOPMENT
Civil Society Engagement with the GEF
Evaluation of Second Interregional Meeting on South-South Cooperation
Malcolm Johnson, Director, Telecommunication Standardization Bureau
Overview of Good Regulatory Practice
An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
THE LABOUR ADMINISTRATION AND INSPECTION PROGRAMME LAB/ADMIN
An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
Presentation transcript:

1 IMPACT: the International Medical Products Anti-Counterfeiting Taskforce Peter Munyi LLM Christa Cepuch BSc Phm UNSR EAC Consultation, Nairobi 10 – 12 Sept 2010

2 PLAYING WITH WORDS CAN BE DANGEROUS “ … the IP enforcement campaign is characterised by strategic obfuscation; its message is intentionally misleading…” Sell, Susan (2008)

3

4 WHAT IS IMPACT? Est 2006 “A voluntary groupings of governments, organisations, institutions, agencies and associations from developing and developed countries … aimed at building coordinated networks across and between countries in order to halt the production, trading and selling of fake medicines around the globe.“ Mission: “To promote and strengthen international collaboration to combat counterfeit medicinal products...” SEE TERMS OF REFERENCE Goals: “ Develop technical and administrative tools to support establishment or strengthening of international, regional and national strategies.” Norm setting?

5 WHO’s ROLE IN IMPACT Participants: IGOs such as WHO; EC; Interpol, IFMPA, WIPO, WCO, OECD, EC, NMRAs (governmental institutions and agencies); WHO collaborating centres; NGOs active in combating counterfeit medicinal products (?); international associations representing manufacturers etc. WHO is just one of the voluntary participants Secretariat: “subject to...human and financial resources, secretarial support for the IMPACT will be provided by WHO....” “IMPACT documents...issued by WHO will be disseminated with appropriate disclaimers...” “the secretarial support... will be financed by voluntary contributions from participants.”

6 IMPACT WORKING GROUPS Working Groups  Legislative and Regulatory Infrastructure to intern alia, develop model legislation and initiatives aimed at law-makers in orders to promote adoption of new legislation  Regulatory Implementation  Enforcement  Technology  Communication

7 LEGISLATIVE AND REGULATORY INFRASTRUCTURE Some of the outcomes of the IMPACT WG on Legislative and Regulatory infrastructure: 1. Principles and Elements of National Legislations (a)Barriers to enforcement (b)Definitions, including defining counterfeiting... (c)Responsibilities (d)Sanctions and types thereof (e)Illegal acts 2. Submit comments to WHO by Prepare for discussions at WHA63 in May 2010

8 WHA63 on IMPACT At WHA63, a resolution was adopted for an intergovernmental WG (IGWG) on counterfeit medicinal products, with participation being open to all member states with a mandate to examine WHO’s:  role in ensuring availability of safe... affordable medicines;  relationship with IMPACT;  role in prevention and control of substandard / spurious / counterfeit medicines This IGWG to report to WHA64 (May 2011)

9 COUNTERFEIT: IMPACT – 1 (IP enforcement.. and.. public health)  Two paragraphs and four notes “… a product with a false representation (a) of its identify (b) and / or source (c). This applies to the product, its container or other packaging or labelling information. Counterfeiting can apply to both branded and generic products. Counterfeits may include products with correct ingredients / components (d), with wrong ingredients / components, without active ingredients, with incorrect amounts of active ingredients or with fake packaging…” (continues)

10 COUNTERFEIT: IMPACT – 2 (IP enforcement.. and.. public health) (continued…) … Violations or disputes concerning patents must not be confused with counterfeiting of medical products. Medical products that are not authorized for marketing in a given country but authorized elsewhere are not considered counterfeit. Substandard batches of, or quality defects or non-compliance with GMP / GDP in legitimate medical products must not be confused with counterfeiting…”

11 COUNTERFEIT: IMPACT - 3 (IP enforcement.. and.. public health)  Provides opportunity for supporters of strong IP regimes to use public health issues as a front to enforce IPRs (e.g. through public health agencies such as NMRAs)  Fear mongering and alarmist as a public relations campaign: fanged cobra (!) representing counterfeit medicines (?)

12 the public’s reaction !

13 THANK YOU!! MERCI BEAUCOUP!! ASANTENI SANA!!